Combinatorial Nutraceutical Supplement Pill (CNSP) stimulates naïve adult telomerase positive stem cells In-Situ to reverse signs and symptoms in multiple human health concerns
1 Dragonfly Foundation for Research and Development, Macon, GA 31210 USA.
2 Henry E Young PhD Regeneration Technologies, Macon, GA 31210 USA.
Research Article
GSC Advanced Research and Reviews, 2024, 20(02), 047–056.
Article DOI: 10.30574/gscarr.2024.20.2.0290
Publication history:
Received on 20 June 2024; revised on 05 August 2024; accepted on 07 August 2024
Abstract:
Previous IRB-approved studies demonstrated that a rare population of endogenous adult telomerase positive stem cells (aTPSCs), isolated and activated ex vivo, displayed a 100% safety record for reinfusion and an 86% efficacy at reversing signs and symptoms in 97 individuals in 18 disease states. Recent studies demonstrated that these rare aTPSCs could also be activated in vivo by ingestion of a combinatorial nutraceutical supplement pill (CNSP). With IRB permission, CNSP was originally developed for an individual too fragile to undergo the fresh isolate aTPSC technologies. Without any other medical intervention, ingestion of CNSP for 12 months raised his ejection fraction from <10% to about 50%. Based on the results from his study (n=1) [100% safe and 100% efficacious], we received IRB permission to expand the number of clinical trials to determine the effectiveness of using CNSP for other health concerns. Herein, are the preliminary results from 40 people in 28 health concerns utilizing CNSP only and CNSP with other treatment modalities, to affect a better quality of life. Participants were assessed in phase-0, open access, open ended clinical trials, for 1-4+ years. Participants in all 28 clinical trials demonstrated 100% safety and 100% efficacy at reversing signs and symptoms in their respective health concerns, giving them an apparent better quality of life.
Keywords:
Adult; Telomerase; Stem Cells; Chronic Diseases
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
